Recent studies performed in the laboratory have established that interleukin-4 (IL-4) used in combination with anti-CD40 monoclonal antibody (MoAb) 89 presented on Ltk-mouse fibroblasts stably expressing human FcyRll/CDw32 (referred t o as the CD40 system) sustains long-term proliferation of normal human B cells. In the present study, B-cell chronic lymphocytic leukemias (B-CLLs) activated through slgs or CD40 were examined for their capacity t o proliferate and differentiate in response to various cytokines. Our results indicate that the outcome of IL-4 stimulation on the in vitro growth of B-CLL depends on the signalling pathway used for their activation. Whereas IL-4 did not display any growthstimulatory effect on B-CLL activated by lg cross-linking agents, it could stimulate DNA synthesis and enhance the viable cell recovery when leukemic B cells were cultured in the CD40 system. Most B-CLL samples were induced for IgM Along the way to the humoral response, multiple proliferative disorders emerge. Among them, chronic lymphocytic leukemias (CLLs) are characterized by the accumulation in the blood of noncycling, mature B cells. B-CLL cells are usually considered to be the malignant counterpart of a normal immunocompetent B-lymphocyte subset characterized by the surface expression of the pan-T antigen CD5.7 Like normal B cells, they also express sIgs and CD40. The origin of the disease is poorly documented, but it is not excluded that an abnormal responsiveness to signals provided by the cellular environment could allow leukemic B cells to escape from the normal maturation process and to spread out despite the complex regulatory network.* Indeed, it has been shown that, unlike normal B cells, B-CLL cells could spontaneously proliferate in vitro in response to IL-2 in the absence of any costimulatory signal?
D has shown that combinations of many cytokines result in a sophisticated network designed to drive the B lymphocyte to terminal differentiation.1s2 According to the early models describing the antigen-dependent maturation process: B cells receive their initial activation signal from antigen binding onto surface Igs and next progress into cycle and differentiate into Ig-secreting cells in response to cytokines. However, recent studies performed with monoclonal antibodies (MoAbs) directed against various surface antigens have shown that several membrane molecules can deliver activation and progression signals to B cells. 4 Recently, two major observations have emphasized the importance of the CD40 antigen for the survival and proliferation of human B cells: (1) germinal center B cells can be rescued from apoptosis after ligation of their CD40 antigen5; and (2) costimulation of normal B cells with interleukin-4 (IL-4) and cross-linked anti-CD40 antibodies promotes long-term proliferation of normal human B cells in vitro. 6 Along the way to the humoral response, multiple proliferative disorders emerge. Among them, chronic lymphocytic leukemias (CLLs) are characterized by the accumulation in the blood of noncycling, mature B cells. B-CLL cells are usually considered to be the malignant counterpart of a normal immunocompetent B-lymphocyte subset characterized by the surface expression of the pan-T antigen CD5.7 Like normal B cells, they also express sIgs and CD40. The origin of the disease is poorly documented, but it is not excluded that an abnormal responsiveness to signals provided by the cellular environment could allow leukemic B cells to escape from the normal maturation process and to spread out despite the complex regulatory network.* Indeed, it has been shown that, unlike normal B cells, B-CLL cells could spontaneously proliferate in vitro in response to IL-2 in the absence of any costimulatory signal?
IL-2 and IL-4 were described as two important factors involved in the regulation of human B-cell proliferation and differentiation.l.2 We detail here the influence of two activation pathways initiated by sIgs or CD40 cross-linking, synthesis upon Staphylococcus aureus strain Cowan I stimulation. This Ig response was potentiated by IL-2 and antagonized by IL-4. Anti-CD40 MoAb used alone or in combination with cytokines (IL-la t o IL-6, interferon y, tumor necrosis factory, and transforming growth factor f3) failed t o induce Ig secretion from B-CLL cells. No evidence for Ig isotype switching was obtained with the cytokines listed above, regardless of the mode of activation. Taken together, our results suggest that B-CLL cells can be partially released from their apparent maturation block by IL-2 and Ig crosslinking agents. In contrast, combinations of IL-4 and crosslinked anti-CD40 antibodies induced entry of B-CLL cell into cycle, but poorly stimulated their differentiation into Ig secreting cells. 0 1992 by The American Society of Hematology.
respectively, on the response of B-CLL cells to IL-2 and IL-4.
MATERIALS AND METHODS

Reagents.
Insolubilized anti-IgM antibodies were purchased from BioRad Laboratories (Richmond, CA) and were used at the final concentration of 10 FglmL. Formalinized particles of Staphylococcus aureus strain Cowan I (SAC) were purchased as Pansorbin from Calbiochem-Behring Corp (La Jolla, CA) and were used at the final concentration of 0.005% (vol/vol).
The MoAbs and polyclonal antibodies used for phenotyping the leukemic B-cell preparations were purchased from the following manufacturers.
Fluorescein-conjugated anti-CD5 (Leu l), anti-CD19 (Leu 12), anti-CD20 (Leu 16), anti-CD14 (Leu M3), antLCD10 (Calla), anti-HLA DR, and anti-CD25 (Tac) MoAbs were from the Becton Dickinson Monoclonal Center (Mountain View, CA).
Fluorescein-conjugated anti-CD3 (IOT3), anti-CD2 (IOTll), and anti-CD21 (IOBla) MoAbs were from Immunotech (Luminy, France).
Fluorescein isothiocyanate (F1TC)-conjugated F(ab)'Z fragments of goat antihuman IgM, IgD, IgA, and IgG antibodies were from Dako (Glostrup, Denmark).
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FITC-conjugated F(ab)'n fragments of goat antimouse IgG and IgM used for indirect immunofluorescence stainings were from Bioart (Meudon, France).
The anti-CD40 MoAb 89 and the antLCD23 MoAb 25 were prepared in the laboratory, as described elsewhere.lOJ1
The MoAbs used for the negative selection of B cells with magnetic beads were purchased from the following manufacturers.
Anti-CD2 and anti-CD3 MoAbs were from Aster Laboratories (La Gaude, France).
Anti-CD14 MoAb was from Immunotech. The antibodies used for the determination of Igs levels by enzyme-linked immunosorbent assay (ELISA) were purchased from the following manufacturers:
Alkaline phosphatase-conjugated anti-IgG antibody, nonconjugated antihuman IgG and IgM antibodies, and human standard serum were from Behring (Marburg, Germany).
Nonconjugated antihuman IgA antibodies and alkaline phosphatase-conjugated anti-IgM and anti-IgA antibodies were from Biosys (CompiBgne, France).
Cell staining was performed as described previouslylz and samples were analyzed with a FACScan (Becton Dickinson, Sunnyvale, CA). Propidium iodide (2 pg/mL) was added to each sample before flow cytometry analysis to gate out nonviable cells. The negative control was performed with an isotype-matched unrelated MoAb. The phenotype of proliferating cells was determined by double-fluorescence analysis. Briefly, 1 x lo6 cells were incubated for 45 minutes at 37°C with 10 pmol/L of Bisbenzimide H 33342 fluorochrome (Hoechst fluorochrome; Behring Diagnostics, La Jolla, CA). Direct immunofluorescence staining was then performed using anti-CD5, anti-K, and anti-A antibodies. Samples were analyzed with a FACS star (Becton Dickinson) equipped with a dual laser.
Each of the cytokines listed below was tested at various doses chosen above and below the optimal concentration point determined in specific bioassays as described p r e v i o~s l y .~~ For the sake of clarity, only the optimal concentration value is mentioned here. Except where indicated, all cytokines were used under the form of purified recombinant material. IL-la (1 x 108 U/mg), IL-6 (1 x lo7 U/mg), and tumor necrosis factor a (TNFa) (2 x lo7 U/mg) were purchased from Genzyme (Boston, MA) and were routinely assayed at the final concentration of 100 U/mL, 5 ng/mL, and 25 ng/mL, respectively. IL-2 (3 x IO6 U/mg) and interferon y (IFNy) (1 x IO7 U/mg) were purchased from Amgen Biologicals (Thousand Oaks, CA) and were routinely used at the final concentrations of 20 U/mL and 500 U/mL, respectively. IL-5, semipurified by affinity column chromatography from culture supernatants of Cos 7 cells transfected with the IL-5 cDNA clone, was kindly provided by Dr R. Coffmann (DNAX, Palo Alto, CA) and was used at 15 ng/mL. IL-3 (5 x 1 8 U/mg), granulocytemacrophage colony-stimulating factor (GM-CSF) (2 x lo6 U/mg), and IL-4 (1 x lo7 U/mg) were kindly provided by Drs S. Tindall, T.L. Nagabhushan, and P. Trotta (Schering-Plough Research Institute, Bloomfield, NJ). They were assayed at 10 ng/mL, 100 ng/mL, and 500 U/mL, respectively. Transforming growth factor p (TGFP; R and D Systems, Minneapolis, MN) was usually tested at 0.6 ng/mL, except where indicated. BAR was treated by corticoids at the time of the study. All other patients had not received any chemotherapy in the 3 months preceding this study. Nine samples were obtained from blood and two were obtained from spleen. To evaluate differentiation of B-CLL cells into Ig-secreting cells, 1 x 105 leukemic B cells were cultured for 10 days into roundbottom microtiter plates under a final volume of 200 p,L in the enriched medium described above. Ig levels were measured in culture supernatants by standard ELISA techniques as described eIsewhere.l6J7 Each culture point was performed in quadruplicate.
RESULTS
patients (5 women and 6 men,aged 26 to 85) having the clinical and immunophenotype criteria for B-CLL. As summarized in Table 1 higher than that of the negative control).
because no positive staining was observed with anti-CD2, anti-CD3, and anti-CD14 MoAbs. For all leukemic specimens examined, the results of the phenotypic analysis were compatible with the diagnosis of B-CLL,'s because the pan-Bxell markers (CD19, CD20, and CD40) were coexpressed with CD5 on more than 95% of cells with the exception of patient POT, for which CD5 was only distributed on 65% of cells. The low expression of surface Igs on five B-CLL specimens is in accordance with previously reported data.I8 IgM was the predominant isotype expressed by B-CLL because only 1 of 11 cases (BAI) appeared to express a downstream heavy chain isotype. It is noteworthy that IgG was coexpressed with IgM on the leukemic cells from patient BAI, a feature that has also been observed in some cases of hyper IgM immunodeficiency. 19 The observation that all B-CLL cases studied exclusively expressed one type of light chain argues in favor of the monoclonality or oligoclonality of the B-cell populations examined and suggests that normal B cells were virtually absent from the leukemic cell suspensions. Surprisingly, B-CLL cells from patient POT homogeneously expressed a single light chain isotype despite the presence of two B-cell subsets within this population as suggested by the heterogenous expression of CD5 on these cells (65% CD5+ cells). Although the surface expression of CD23 was highly variable from one sample to another, the intensity of expression of this marker was generally found to be higher than that observed on resting B cells isolated from healthy donors.20 Proliferative response of B-CLL cells to polyclonal B-cell activators is heterogenous. As illustrated by Table 3 , B-CLL cells displayed a rather heterogenous pattern of growth response to polyclonal B-cell activators, precluding any attempt of a simple classification. Indeed, three samples (GER, PON, and PAS) were found to be only marginally responsive to B-cell stimulants used alone, four samples (PIG, BAR, BOL, and BAE) incorporated [3H]-thymidine essentially in response to SAC, one sample (FLA) responded to anti-IgM and anti-CD40 antibodies, two samples (POT and MAG) responded to SAC and anti-CD40, and B-CLL cells from patient BAI were stimulated for DNA synthesis by all polyclonal activators used. However, it should be stressed that, in most cases, the growth stimulus provided by cross-linked anti-CD40 was at least twofold lower than that provided by anti-Ig reagents as estimated by the [3H]-thymidine incorporation levels. No difference was observed in the pattern of growth response of B-CLL cells to cytokine between the SAC and the anti-IgM activation systems (data not shown). However, due to the low levels of background DNA synthesis elicited by anti-IgM antibodies, this activator was generally prefered to SAC for illustrating the proliferative responses of B-CLL cells to cytokines.
The proliferative response of B-CLL to IL-4 depends on the model of activation. B-CLL cells originating from six different patients were then stimulated with IL-la, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IFNy, TNFa, and GM-CSF in the presence of insolubilized anti-IgM antibodies or in the An opposite pattern of growth response was observed when B-CLL cells were activated by cross-linked anti-CD40 MoAb (Fig 1B) because most leukemic clones (4 of 6) displayed a proliferative response to IL-4 in this activation system. In contrast, the growth response of anti-CD4S activated B-CLL cells to IL-2 was reduced when compared with the Ig signalling pathway. IFNy stimulated the DNA synthesis of most B-CLL samples activated through CD40, whereas TNFa was consistently ineffective when used in combination with cross-linked anti-CD40 MoAb. The titration of the growth-promoting effect of IL-4 on the B-CLL specimen BOL (Fig 2) showed that a plateau of stimulation was reached for =50 U/mL of IL-4, which is comparable with the maximal stimulatory effect observed in normal B-cell ~u1tures.l~ The unresponsiveness of anti-IgMactivated B-CLL cells to the growth stimulatory effect of IL-4 could not be overcome by using high concentrations of IL-4 (1,000 U/mL).
To rule out the possibility that the apparent lack of responsiveness of anti-Ig-activated B-CLLs to IL-4 could be due to a delayed responsiveness of the cells, the growth response of the B-CLL clone POT to IL-4 activated through sIgs or CD40 was measured at different time intervals. As shown in Fig 3, the growth stimulatory effect of IL-2 persisted at day 7, but B-CLL cells constantly remained unresponsive to IL-4 even after prolonged culturing. In contrast, after ligation of the CD40 antigen, the levels of stimulation reached with IL-2 were barely significant at each time point, whereas the growth response of cells to IL-4 increased from day 3 to day 7.
IL-4 induces proliferation of B-CLL cells activated through CD40. DNA synthesis induced by IL-4 and anti-CD40 in B-CLL cells truly reflected B-cell proliferation because the number of input cells was found to increase with time ( Fig  4B) . As shown in Table 4 , an increase in the viable cell recovery was observed in five of seven cases when cocultured for 10 days with IL-4 in the CD40 system. These data correlated with [3H]-thymidine uptake values. Indeed, B-CLL cells from patients PAS, FLA, and PON, whose cell numbers increased twofold to fourfold, showed important [3H]-thymidine incorporation in response to IL-4 and anti-CD40 MoAb (Figs 1 and 4) , whereas B-CLL cells from patients BAE and BAR, whose cell numbers remained constant, only marginally enhanced their DNA synthesis under the same conditions (Fig 1) . Although IL-2 had been shown to stimulate DNA synthesis in B-CLL cells activated through sIgs, it only moderately enhanced the number of viable cells in the early phases of the culture (Fig 4A) . We next examined whether the IL-4-responsive population in the CD40 system was composed of normal or leukemic B cells. For this purpose, double-staining experiments were performed in which cycling cells were visualized with Hoechst fluorochrome and leukemic cells were identified on the basis of the expression of CD5 or of a single type of light chain. As shown in Fig 5, in a typical Table 5 , three B-CLL specimens (PIG, GER, and BAE) were significantly induced to secrete IgM upon activation with SAC in the absence of exogenous factor. The addition of IL-2 enhanced the Ig production of the majority of B-CLL samples activated by SAC (7 of 9 cases), whereas the addition of IG4 weakly reduced this IgM production in 5 of 9 cases. In contrast, cross-linked antbCD4O MoAb used alone or in combination with IL-2 or IL-4 failed to stimulate Ig secretion from B-CLL cells. As previously described on normal B cells, activation by anti-IgM antibodies did not enhance Ig p r o d u c t i~n .~~,~~ None of the other cytokines previously assayed for their capacity to stimulate the in vitro growth of B-CLL cells (IGla, IL-3, IL-5, IL-6, IL-7, IFNy, TGFP, TNFa, and GM-CSF) was found to stimulate Ig synthesis from the leukemic specimens examined, regardless of the activation stimulus applied (data not shown). Additionally, it is noteworthy that neither IL-4 nor TGFP, which have been shown to be involved into isotype switching to IgE24 and IgA,25 respectively, could induce B-CLL cells to switch to these downstream heavy chain isotypes.
DISCUSSION
In the present report, we show that the outcome of IL-4 and IL-2 stimulation on the in vitro growth of B-CLL cells depends on the activation pathway. Indeed, IL-4 used in costimulation with anti-Ig reagents failed to stimulate DNA synthesis in most of the leukemic samples examined, but supported their growth when they were activated through CD40. We have shown that normal CD5+ and CD5-B cells displayed identical growth and differentiation requirements.26 In particular, IL-4 behaved as a growth factor for both B-cell populations in the anti-Ig activation system. Therefore, the unresponsiveness of anti-Ig-activated B-CLL to the growth stimulatory effect of IL-4 relates to the leukemic transformation rather than to an innate property of the CD5+ B-cell compartment. As previously observed with normal B cells,13 IL-2 only moderately enhanced proliferation of B-CLJ., cells in the anti-CD40 activation system. The double-staining experiments showing that all B 10. lg levels were determined by ELISA. In all cases, standard deviation never exceeded 10% of the mean value.
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